Core Viewpoint - The company, Zhaoyan New Drug (06127.HK), reported significant growth in its 2025 annual performance, with a revenue of RMB 1.658 billion and a net profit attributable to shareholders of RMB 299 million, reflecting a substantial year-on-year increase of 302.1% [1] Group 1: Financial Performance - In 2025, the company achieved a revenue of RMB 1.658 billion and a net profit of RMB 299 million, marking a year-on-year growth of 302.1% [1] - The company proposed a final dividend of RMB 0.12 per ordinary share [1] Group 2: Industry Context - The domestic biopharmaceutical industry maintained stable investment and financing activity in 2025, showing signs of recovery [1] Group 3: Business Development - The company focused on enhancing market expansion and technological empowerment, driving growth across all business lines [1] - The total order amount on hand was approximately RMB 2.6 billion, with new signed orders also around RMB 2.6 billion [1] Group 4: Quality and Innovation - The company emphasized maintaining business quality and operational standards, ensuring data authenticity and accuracy [2] - Continuous professional training and capability enhancement for personnel were conducted to ensure the scientific and uniform quality of projects [2] - The company is committed to technological innovation to meet the evolving research and development needs, thereby solidifying its leading position in the industry [2] - Project management processes and quality management systems were further optimized to enhance customer satisfaction and support business growth [2]